First Horizon Advisors Inc. grew its position in SPDR S&P Biotech ETF (NYSEARCA:XBI – Free Report) by 43.8% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 821 shares of the exchange traded fund’s stock after acquiring an additional 250 shares during the period. First Horizon Advisors Inc.’s holdings in SPDR S&P Biotech ETF were worth $73,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also modified their holdings of XBI. James J. Burns & Company LLC lifted its position in shares of SPDR S&P Biotech ETF by 5.0% during the third quarter. James J. Burns & Company LLC now owns 3,062 shares of the exchange traded fund’s stock worth $224,000 after purchasing an additional 146 shares in the last quarter. Greenwich Wealth Management LLC boosted its position in SPDR S&P Biotech ETF by 1.4% in the 4th quarter. Greenwich Wealth Management LLC now owns 11,451 shares of the exchange traded fund’s stock valued at $1,022,000 after buying an additional 155 shares during the last quarter. Moser Wealth Advisors LLC increased its stake in shares of SPDR S&P Biotech ETF by 10.4% in the 3rd quarter. Moser Wealth Advisors LLC now owns 2,041 shares of the exchange traded fund’s stock valued at $149,000 after buying an additional 193 shares during the period. HB Wealth Management LLC increased its stake in shares of SPDR S&P Biotech ETF by 4.9% in the 4th quarter. HB Wealth Management LLC now owns 4,280 shares of the exchange traded fund’s stock valued at $382,000 after buying an additional 200 shares during the period. Finally, Avaii Wealth Management LLC raised its position in shares of SPDR S&P Biotech ETF by 5.5% during the fourth quarter. Avaii Wealth Management LLC now owns 3,870 shares of the exchange traded fund’s stock worth $346,000 after acquiring an additional 203 shares during the last quarter.
SPDR S&P Biotech ETF Stock Down 0.2 %
SPDR S&P Biotech ETF stock opened at $90.43 on Wednesday. The stock has a market cap of $6.89 billion, a price-to-earnings ratio of 11.47 and a beta of 1.11. SPDR S&P Biotech ETF has a 12-month low of $63.80 and a 12-month high of $103.52. The business’s 50-day simple moving average is $91.68 and its 200 day simple moving average is $85.77.
SPDR S&P Biotech ETF Profile
SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.
Further Reading
- Five stocks we like better than SPDR S&P Biotech ETF
- Best ESG Stocks: 11 Best Stocks for ESG Investing
- Garmin Navigates to New Highs Driven By Wearables Trend
- 3 Ways To Invest In Coffee, Other Than Drinking It
- Pinterest Prospers From AI Boosting Shop-Ability and Relevance
- What does consumer price index measure?
- AbbVie Tracking for New Highs in 2024
Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.